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1. Purpose
The aim of this guideline is to assist Nuclear Medicine 
Physicians in the evaluation, safe administration and follow-
up (assessment of response and long-term toxicities) of 
patients with neuroendocrine tumours (NETs) referred for or 
considered for peptide receptor radionuclide therapy (PRRT). 
This practice guidance was written based on recent 
publications and opinions of experts routinely using this 
treatment modality in patient management.
2. Definitions 
PRRT: Peptide receptor radionuclide therapy is the 
administration of a radiopharmaceutical consisting of a beta 
emitting radionuclide chelated to a peptide. In the treatment 
of NETs, the peptide is a ligand for the membrane-bound 
somatostatin receptors. The beta particles emitted by the 
radionuclide in turn cause DNA damage leading to tumour 
cell death. The peptide serves as a guidance molecule which 
homes the beta-emitting radionuclide to the tumour expressing 
somatostatin receptors. This results in targeted tumour death.
Somatostatin: (SST) is a 14 or 28 amino acid peptide with 
anti-secretory properties. It occurs naturally mostly in the 
central nervous system and gastrointestinal tract. The naturally 
occurring SST has a short half-life due to rapid degradation 
in vivo. Synthetic analogues of SST have longer biological 
activity in vivo. Octreotide is an 8-amino-acid derivative of 
SST.
Somatostatin receptors: (SSTRs) are a group of G protein-
coupled membrane-bound receptors that SST and its long-
acting analogues interact with to trigger their biologic 
effects. SSTRs are overexpressed at the cell surface of a large 
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variety of neuroendocrine tumours. Five main subtypes of 
SSTRs have been cloned, SSTR 1 to 5. Naturally occurring 
somatostatin is able to bind to all subtypes of SSTRs but its 
analogues show major differences in their affinities for the 
receptor subtypes. Various types of neuroendocrine tumours 
express the SSTRs in different proportions. SSTR2 is most 
predominantly expressed by NETs and is therefore commonly 
targeted for imaging and endoradiotherapy.
Lutetium-177: (Lu-177) is a radiometal that decays by 
emitting both gamma and beta particles. It has a physical 
half-life of 6.7 days. Its two gamma particles have energies 
of 113 keV (6% relative abundance) and 208 keV (11% 
relative abundance), and are useful for post-therapy imaging 
and for dosimetry calculation. The maximum and average 
energies of the beta particles are 0.498 MeV and 0.133 MeV 
respectively with a corresponding maximum and mean soft-
tissue penetration of 1.7 mm and 0.23 mm.
Yttrium-90: (Y-90) is a radiometal that only emits beta 
particles. It has a physical half-life of 2.7 days. The maximum 
and mean energies of the beta particle emissions are 2.28 MeV 
and 0.934 MeV respectively. It has higher tissue penetration 
compared with Lu-177 with maximum and mean soft-tissue 
penetration depths of 11 mm and 4 mm respectively.
DOTATATE: DOTA, 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid, is a bifunctional chelator that binds 
the beta emitting radiometal to the synthetic octreotide. 
DOTATATE is therefore a derived somatostatin analogue 
peptide which is an abbreviated form of [DOTA0,Tyr3]-
octreotate where Tyr3-octeotide is the synthetic octreotide 
analogue. DOTATATE has high affinity for the SSTR2 receptor 
with no significant affinity for other receptor subtypes.1
DOTATOC: It is an abbreviation for DOTA0,Tyr3-
octreotide. Similar to DOTATATE in that DOTA represents 
the bifunctional chelator and Tyr3-octrotide is the synthetic 
octreotide analogue. The octreotide analogue used in 
DOTATATE has a threonine residue at the C-terminal instead 
of the corresponding amino alcohol of the octreotide analogue 
used in DOTATOC. DOTATOC shows the highest affinity 
for the SSTR2 receptor with a weaker affinity for SSTR3 and 
SSTR5.1
3. Background information 
NETs are a heterogeneous group of neoplasms that 
overexpress SSTRs on their cell surface. They arise from the 
endocrine cells which are widely dispersed in the body. This 
explains NETs occurrence in many organs of the body.2
NETs may be functional or non-functional. Functional NETs 
secrete bioactive amines and peptide hormones in accordance 
with their tissue of origin.3 Patients with functional NETs are 
likely to be diagnosed earlier with their disease becoming 
symptomatic whilst the tumour is still relatively small. NETs 
are commonly found in the gastroenteropancreatic (GEP) 
tissues where they may secrete distinct hormones which 
influences their clinical presentation. The common types of 
functional NETs include carcinoid, insulinoma, gastrinoma, 
glucagonoma, VIPoma, and somatostatinoma. Non-functional 
NETs are commonly slow growing and may only come to 
clinical detection when they are widely metastatic due to 
their slow onset of symptom. Other tissues where NETs are 
commonly found include broncho-pulmonary, genitourinary, 
breast, and skin.
NETs have previously been described as rare tumours. 
Their incidence is however rising due to increased awareness 
amongst physicians and improvements in biochemical 
testing and diagnostic imaging.4-6 An increasing number of 
patients are now diagnosed when the tumours are incidentally 
detected during diagnostic evaluations for unrelated medical 
conditions. Patients with genetic predisposition to developing 
NETs are also now actively sought and followed-up. Many 
patients with genetic predisposition to NETs are offered 
prophylactic surgery, for example, total thyroidectomy to 
prevent the development of medullary thyroid cancer.
The World Health Organization (WHO) has classified 
NETs into three groups based on the tumour growth rate as 
demonstrated on histological examination:7 
• G1 tumours – slow growing well-differentiated tumour 
(Ki-67 ≤ 2%, mitoses/10 high-power fields < 2)
• G2 tumours – heterogeneous tumours with moderate level 
of differentiation (Ki-67 > 2% but ≤ 20%, mitoses/10 
high-power fields 2-20)
• G3 tumours – poorly differentiated aggressive tumours 
(Ki-67 > 20%, mitoses/10 high-power fields > 20)
All well-differentiated neoplasm regardless of their 
metastatic status are called neuroendocrine tumours (NETs). 
They are sub-classified as either G1 or G2 based on their 
Ki-67 index. All poorly differentiated neoplasms are termed 
neuroendocrine carcinomas (NECs) and are graded G3 
(Ki-67 > 20%).8 It is now known that the G3 pancreatic tumour 
consists of two distinct tumour subtypes: a well-differentiated 
but highly proliferative group of tumours (Ki-67 > 20%) 
and a group of poorly differentiated small and large NECs.9 
The 2017 WHO classification of pancreatic neuroendocrine 
neoplasms has now recognised G3 NETs as a separate entity 
from NECs.10
Disease staging is essential following histological 
confirmation of the diagnosis. Accurate staging is crucial in 
determining appropriate therapy. It is important to identify 
those patients with localised disease in whom disease 
may be amenable to curative surgical excision. In patients 
with advanced disease, imaging plays an essential role in 
determining invasion of tumour into contiguous organs as 
well as sites of distant metastases. Several organizations 
including the American Joint Committee on Cancer (AJCC), 
European Neuroendocrine Tumour Society (ENETS), WHO 
and the Union for International Cancer Control (UICC) have 
individually or jointly proposed staging systems for some 
of the most common types of NETs.7,11,12 Tumour grading 
and disease stage have prognostic value in patients with 
NETs.7,13-15
Conventional imaging with contrast-enhanced computed 
tomography (ceCT) and magnetic resonance imaging (MRI) 
are the primary investigations obtained in staging and re-
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staging of disease. Three-phase examination of the liver on a 
ceCT is essential for adequate evaluation of liver involvement. 
MRI is useful for the evaluation of liver, pancreas, bone 
marrow and brain involvement. Ultrasound is a useful 
modality to provide guidance for image-guided biopsy.16
Functional imaging with Gallium-68 (Ga-68) DOTA-
peptide (including Ga-68 DOTATATE, Ga-68 DOTATOC and 
Ga-68 DOTANOC) has demonstrated the highest sensitivity 
and specificity in the evaluation of most types of NETs with an 
overall sensitivity of > 90% and specificity ranging between 
92 and 98%.1,17 Positron emission tomography (PET) imaging 
with Ga-68 DOTA-peptide has superiority over single photon 
emission tomography (SPECT) imaging with Indium-111 or 
Tecnetium-99m octreotide.18,19 
Studies have demonstrated the strengths of Ga-68 DOTA-
peptide over conventional anatomic imaging with computed 
tomography (CT) or MRI in the evaluation of patients with 
NETs.19-21 It is better than CT at detecting bone metastases due 
to neuroendocrine tumour.22 In a study, Ga-68 DOTATATE 
PET/CT was found to outperform standalone ceCT in the 
detection of neuroendocrine tumour metastases in the bones 
and lymph nodes. Both modalities had similar sensitivity in 
the detection of pulmonary metastases but Ga-68 DOTATATE 
had a significantly higher specificity.23 The excellent soft 
tissue resolution of MRI combined with the high sensitivity 
of Ga-68 DOTA-peptide may make combined functional and 
morphologic imaging with Ga-68 DOTA-peptide PET/MRI a 
useful modality for imaging especially for lesion detection in 
the pancreas and liver.24
4. Treatment options for neuroendocrine  
    tumours
Several therapy options are available for the treatment of 
neuroendocrine neoplasms depending on disease stage, 
tumour differentiation, genetic alterations in the tumour, 
among others. It is therefore prudent that therapy decision be 
undertaken in a multidisciplinary team including Endocrine 
Surgeons, Oncologists and Nuclear Physicians.
Surgical resection with curative intent is the treatment 
of choice in patients with localised disease and in patients 
with liver/lymph node metastases.25 Surgical resection of the 
primary tumour in patients with metastatic NETs may reduce 
the incidence of complications such as intestinal obstruction 
and may have survival benefit.26 Surgical de-bulking of 
tumours may be undertaken in patients with large tumours. 
In patients with liver metastases which are not 
resectable, liver-directed therapies such as trans-arterial 
chemoembolization, trans-arterial embolization (TAE), 
radiofrequency ablation, and selective internal radiation 
therapy (SIRT) may be employed to down-stage liver 
metastases so that they can be resected. If employed earlier in 
the disease course, TAE has been shown to be associated with 
better tumour response and overall survival. These treatments 
may also be offered for symptom control in functional NETs.27 
In patients with advanced disease that is not amenable to 
curative surgical resection, treatment is directed at controlling 
excess hormone secretion by the tumour cells and inhibition 
of the tumour. The long-acting somatostatin analogues, 
octreotide and lanreotide are currently considered for first line 
treatment. The growth inhibitory effect of the somatostatin 
analogues is the basis for their use even in non-functional 
NETs expressing SSTR2 with rapid tumour growth.28
The CLARINET study is a phase III trial that randomised 
patients with grade 1 or 2 gastroenteropancreatic NETs to 
either receive an extended-release form of lanreotide (n=101) 
or placebo (n=103). The primary end point was progression-
free survival (PFS). Lanreotide was found to be associated 
with a significant PFS compared with placebo with a PFS at 
24 months of 65.1% (95% CI, 54.0 to 74.1) for the lanreotide 
group compared with 33.0% (95% CI, 23.0 to 43.3) for the 
placebo group.29 The PROMID trial randomly assigned 
treatment-naïve patients with mid-gut well-differentiated 
metastatic NETs to either placebo or 30 mg intramuscular 
injection of octreotide LAR.30 Median time to tumour 
progression was 14.3 months in the octreotide group versus 
6 months in the placebo group (hazard ratio=0.34; 95% CI, 
0.20 to 0.59, p=0.000072). No difference in response rates was 
seen in patients with functional NETs compared to patients 
with non-functional NETs.
NETTER-1 is a phase III trial that randomly assigned 
patients with well-differentiated metastatic midgut 
neuroendocrine tumours to either receive Lu-177 DOTATATE 
every 8 weeks with best supportive care including 30 mg 
intramuscular injection of long-acting repeatable (LuTATE 
group, n=116) or 60 mg intramuscular injection of LAR 
octreotide every 4 weeks (control group, n=113).31 The 
estimated PFS at 20 months was 65.2% (95% CI, 50.0 to 76.8) 
in the LuTATE group and 10.8% (95% CI, 3.5 to 23.0) in the 
control group. The response rate was 18% in the LuTATE 
group compared with 3% in the control group (p < 0.001). 
Grade 3 or 4 neutropenia and thrombocytopenia were seen 
in 1% and 2% respectively of patients in the LuTATE group 
compared with none in the control group. No evidence of 
renal toxicity was reported in the study.
The 2010 WHO tumour grade is an important factor to be 
considered in deciding on appropriate tumour-targeted therapy. 
In patients with poorly differentiated, rapidly proliferating 
G3 NEC, chemotherapy is indicated. Chemotherapy may 
also be indicated in patients with extra-pancreatic NETs (e.g. 
bronchial, thymus, stomach, colon, rectum) with Ki-67 in 
the upper G2 range. Other situations in which chemotherapy 
may be considered include rapid tumour progression in less 
than 6 to 12 months, as neoadjuvant therapy to downstage 
tumour to allow for surgical resection, following failure 
of other therapies, large tumour bulk, and in the event of a 
negative somatostatin-based functional imaging.25 Cisplatin 
or carboplatin with etoposide are preferred for NECs. 
Chemotherapy with agents such as 5-FU, capecitabine, 
dacarbazine, oxaliplatin, streptozocin, and temozolomide 
in different combinations may be used in G1 or G2 tumours 
when indicated.32-34 Chemotherapy has limited utility in 
patients with slow-growing well-differentiated tumour.
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The utility of molecular target agents is being evaluated 
in several clinical trials. These agents target different 
pathways in tumourigenesis. Everolimus is a mTOR inhibitor 
associated with improved PFS. The RADIANT-3 study 
reported the overall survival (OS) in patients with advanced, 
progressive, low- to intermediate-grade pancreatic NETs 
randomly assigned to everolimus or placebo.35 Everolimus 
was associated with an OS of 44.0 months compared with OS 
of 37.7 months in the placebo group (survival benefit of 6.3 
months). This survival benefit was however not significant 
(p=0.30). In the updated progression-free survival and overall 
survival from the double-blind, placebo-controlled trial that 
randomised patients with advanced, well-differentiated, 
progressive pancreatic neuroendocrine tumour to either 
receive 37.5 mg/day sunitinib (n=86) or placebo (n=85), 
median progression-free survival was 12.6 months (95% CI: 
11.1-20.6) for sunitinib versus 5.8 months for placebo group 
(95%CI: 3.8-7.2) (hazard ratio, 0.32; 95% CI 0.18-0.55; 
p=0.000015). There was however no significant difference in 
the overall survival between the two groups.36
5. Indications and contraindications 
 5.1 Indications
PRRT with Lu-177 DOTATATE or Y-90 DOTATOC is 
indicated in patients with SSTR2 positive metastatic or 
inoperable NETs.31,37-40 The ideal patient must have a well- to 
moderately-differentiated tumour (2010 WHO G1 and G2). 
Published data are most robust for use of PRRT in patients with 
SSTR-expressing gastroenteropancreatic and bronchial NETs. 
Other NETs such as pheochromocytoma/paraganglioma, 
neuroblastoma and medullary thyroid carcinoma are possible 
indications for PRRT.41-43 In view of the highly heterogeneous 
nature of G3 tumours,44,45 PRRT may be considered in patients 
with G3 pancreatic NETs whose lesions demonstrate tracer 
avidity on Ga-68 DOTA-peptide imaging.46,47 
The decision to consider patients with G3 NETs for PRRT as 
well as the need for addition of radio-sensitising chemotherapy 
to therapy should be made in a multidisciplinary setting.
The ideal candidate for PRRT should fulfil these criteria:
• Histologically confirmed well-differentiated NET- or 
moderately-differentiated NETs, G1 or G2
• Advanced disease that is not amenable to curative surgery
• Progressive disease 
• SSTR2 positive disease demonstrated on functional 
imaging (intensity of tracer uptake in lesions greater than 
the physiologic uptake within normal liver tissue) which 
is concordant with morphological imaging. If there is 
discordance, an FDG PET/CT should be done to assess 
concordance with SSTR2 positive disease
• Karnofsky performance status above 60% or ECOG 
performance status < 2.
5.2 Contraindications
Absolute
• Pregnancy
• Severe acute intercurrent illness 
Relative
• Poor bone marrow reserve: white blood cell count 
< 2,000/µL, platelet count < 75,000/ µL, haemoglobin 
concentration < 8 g/dL.
• Severely impaired renal function: serum creatinine > 150 
µmol/L. Y-90 and Lu-177 used in PRRT undergo tubular 
reabsorption following their filtration at the glomerulus. 
Patients with obstruction in their renal outflow tract have 
a high radiation dose delivered to their kidneys. Such 
patients are recommended to undergo a procedure to 
relieve outflow obstruction before they are submitted to 
PRRT.
• Compromised liver function: total bilirubin level > 3 
times upper limit of normal, serum albumin < 3.0 g/dL. 
6. Procedure
6.1 Facility and personnel
PRRT is a radionuclide therapy and must be used in compliance 
with the national regulations. It must be administered in an 
appropriately equipped facility licensed by the radiation 
control unit of the Department of Health (DoH) as suitable 
for the safe administration of radionuclide therapies. The 
facility must be staffed with personnel who are well trained 
in the safe use of unsealed radiation sources including waste 
management and handling of accidental contamination of 
persons and the site. PRRT must be administered by a Nuclear 
Medicine Physician with supporting staff (medical physicist 
and nursing).
6.2 Preparation for therapy
Somatostatin analogues withdrawal: 
Withdrawal of somatostatin analogues (SAs) prior to PRRT 
is still a subject of intense debate. No consensus has been 
reached as to whether its use has any significant impact on 
uptake of Lutetium 177 DOTATATE by the tumour. We 
recommend withdrawal of SAs prior to PRRT. Short acting 
SAs should be withdrawn for 24 hours and long acting SAs 
should be withdrawn for 1 month. 
Once considered for PRRT, the following must be done 
within two weeks of the proposed date of therapy to confirm 
eligibility:
• Review patient history and make a comprehensive 
documentation of it
• Full blood count
• Renal function test – serum creatinine and creatinine 
clearance to estimate glomerular filtration rate. Cr-51 
EDTA or Tc-99m DTPA glomerular filtration rate (GFR) 
determination may be preferred in high-risk patients: 
diabetes, hypertension, previous renal insult, pretreatment 
with chemotherapy, solitary kidney, and children. 
• Radionuclide dynamic renal scintigraphy to evaluate for 
outflow obstruction 
• Liver function tests including international normalised 
ratio (INR) and prothrombin time
• Serum chromogranin A and other relevant tumour-
specific biomarkers for biochemical response assessment
• Perform a comprehensive physical examination including 
performance status determination.
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6.3 Therapy administration
Informed consent must be obtained from the patient prior to 
therapy administration.
Renal protection:
The kidneys are the target organs during PRRT.
Renal protection is indicated to prevent the reabsorption 
of the therapy agent by the tubular cells responsible for renal 
toxicity. This is done by infusion of the positively charged 
amino acids L- lycine and/or L-arginine which compete 
with Lu-177 DOTATATE or Y-90 DOTATOC for tubular 
reabsorption, reducing radiation dose to the kidneys.48 
Different protocols for renal protection have been described.49 
Aminostetil® N-Hepa 8% is an amino acid solution available 
for intravenous infusion in South Africa. We recommend 
intravenous administration of 1.5 to 2 litres of this amino 
acid solution given over 4 hours using an infusion pump. 
Amino acid infusion should be started 30 to 60 minutes before 
administration of the therapy agent. 
Premedication:
Premedication is given prior to commencement of amino 
acid infusion to mitigate against the side effects of its 
administration. These medications are:
• 4 mg intravenous Dexamethasone 
• 8 mg intravenous Ondansetron 
Lu-177 DOTATATE:
Lu-177 DOTATATE is available in South Africa. It is 
delivered to the therapy centre in a ready-to-use form after 
passing all quality control tests and must be administered to 
the patient on the same day. It is administered as follows:
• Activity – 150 to 200mCi (5.55 to 7.4 GBq) in 50 to 
100 mLs of normal saline infused over 30 minutes. Lower 
activity of about 100mCi (3.5GBq) may be considered in 
children.
• Numbers of cycles – 4 to 6
• Treatment interval – 8 to 12 weeks.
Post-therapy images:
Post-therapy images are obtained from imaging the 
208 KeV gamma photons of Lu-177. Whole-body planar 
images obtained at 4-time-points (for example, at 1, 4, 24 
and 48 hours post-therapy) to confirm uptake of therapy 
agents in the tumour and for dosimetry assessment. Further 
delayed imaging may be acquired for dosimetry assessment. 
Additional single photon emission computed tomography and 
computed tomography (SPECT/CT) imaging of the abdomen 
may be performed at 24 hours post-therapy.
Treatment can be performed on an in- or outpatient basis. 
This decision is made by the attending Nuclear Physician and 
is usually based on the patient’s medical condition.
The South African regulations require that patients treated 
with radionuclide therapy must have their exposure rate below 
25 µSv/hr at a distance of 1 metre from the patient before 
discharged home. 
Special precautions:
The treating Nuclear Physician must ensure that the patient 
for PRRT does not have any contraindication to the therapy 
agent or other additional agents routinely administered 
during therapy. For example, dexamethasone should be 
omitted in patients with pheochromocytoma/paraganglioma. 
In paediatric patients, amino acid should be infused at a 
slower rate. 
7. Side effects
7.1 Acute
There are side effects related to amino acid infusion and the 
therapy agent. Infusion of concentrated amino acid solution 
may lead to nausea, headache, abdominal discomfort and 
vomiting due to metabolic acidosis.31,37 Rapid infusion of 
the amino acid solution may cause a patient with borderline 
cardiac function to develop cardiac insufficiency. In this 
category of patients, a lower volume of amino acid solution 
should be administered.49 Electrolyte derangements such as 
hyperkalaemia and hypernatremia may also complicate amino 
acid infusion.
Therapy agent administration may worsen the clinical 
symptoms related to the syndromes present in patients with 
functional NETs. The specific nature of these side effects will 
depend on the type of NETs. Therefore, look out for adrenergic 
crisis in patients with pheochromocytoma/paraganglioma, 
carcinoid crisis in patients with carcinoid tumour, and tumour 
lysis syndrome in patients with large tumours. Patient must 
therefore be monitored continuously throughout their hospital 
stay while being observed for any adverse effect.
7.2 Delayed
Hematotoxicity is the most common delayed side effect 
following PRRT.31,37 This may occur 4 to 8 weeks after 
treatment in the form of anaemia, thrombocytopenia or 
leucopenia.37 Treatment related cancers in the form of 
myelodysplastic syndrome and acute leukaemia have been 
reported in 1–4 % of patients treated with PRRT.31,37,50-53 The 
incidence of treatment-related hematologic malignancies is 
related to the duration of follow-up. The mean latency time 
for the development of myelodysplastic syndrome or acute 
leukaemia in patients treated with PRRT is > 40 months.50,52 
Previous use of myelotoxic chemotherapy and radiotherapy 
to red marrow are strong predictors of hematotoxicity 
following PRRT. Other factors predisposing to hematological 
malignancies are tumour invasion of the bone marrow and 
hematological toxicity grades 3/4 during the course of 
PRRT.50,52
Serious renal toxicity is rare. Factors predisposing to 
deterioration in renal function following PRRT include 
renal outflow obstruction, and pre-existing hypertension and 
diabetes. In the NETTER 1 trial, no patient with grade 3 or 
4 renal toxicity was reported.31 In a separate study, 2 patients 
out of 504 treated with Lu-177 DOTATATE for NETs had 
renal insufficiency, one of whom had a pre-existing renal 
impairment.37
Liver toxicity may be seen in patients with extensive liver 
metastases resulting in irradiation of the limited functioning 
liver tissue.37 Other potential long-term side effects include 
mild hair loss, asthenia, and decreased appetite.
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8. Follow-up
8.1 Between-treatment
During the treatment period, certain biochemical 
investigations should be obtained to detect side effects and 
determine patients’ eligibility for subsequent treatment cycles. 
The following tests should be done two weeks before each 
scheduled treatment cycle:
• Full blood count
• Serum electrolyte, urea and creatinine including estimated 
GFR determination
• Liver function tests including prothrombin time
• Chromogranin A and any other relevant tumour specific 
biomarkers 
• Dynamic renal scintigraphy should be repeated before the 
third and fifth treatment cycles
• Functional and radiological imaging may be considered if 
clinically indicated.
8.2 Post-therapy
After completion of treatment cycles, patients are usually 
referred back to their referring clinicians. It should be 
suggested in the discharge summary that patients should have 
repeat full blood count, liver function test, serum creatinine, 
eGFR and biomarkers done every 12–16 weeks. Morphologic 
imaging with ceCT and/MRI should be done 3–6 months 
after completion of PRRT to document objective response 
to therapy. Ga-68 DOTA-peptide PET/CT imaging provides 
an opportunity for the evaluation of the functional status of 
the disease post-therapy. This functional imaging may be 
done 6–12 months after the last cycle of PRRT. Combined 
morphologic and functional imaging may be complementary 
in post-PRRT assessment. Subsequently, patients should 
have Ga-68 DOTA-peptide PET/CT annually (or sooner if 
clinically indicated) for follow-up.
When there is a discordance between morphologic 
and metabolic imaging which may suggest tumour 
dedifferentiation resulting in loss of avidity of tumour for Ga-
68 DOTA-peptide, F-18 FDG PET/CT should be done. Intense 
avidity of F-18 FDG in tumour, incongruent with finding on 
Ga-68 DOTA-peptide, supports tumour dedifferentiation.53,54 
This may be confirmed by re-biopsy of lesion. Chemotherapy 
should be considered in the retreatment of patients whose 
lesions no longer express the SSTRs.
9. Salvage therapy for recurrent disease
Salvage therapy with PRRT may be considered for 
retreatment with PRRT provided there was no severe toxicity 
to the previous treatment.55,56 This decision must be taken 
in a multidisciplinary setting. Patients being considered for 
retreatment should be evaluated afresh for suitability for 
PRRT as they were initially.
10. Outcome and Goals of Therapy
PRRT in progressive SSTR positive NETs leads to complete 
remission in a minority of patients. The majority of patients 
(70–90%), however, have partial/minor response or stable 
disease. A minority of patients (4–10%) may experience 
progressive disease despite treatment.57-59 Symptomatic 
response is achieved in more than 90% of patients with 
functional NETs.60 Response achieved with PRRT is durable 
with median progression-free survival of 26–33 months and 
median overall of 55–61 months.57-59 Several factors predict 
outcome of treatment. Factors predictive of good therapy 
outcome and long-term survival include low Ki-67 index, 
Karnofsky performance index score ≤ 70%, liver tumour 
burden ≥ 25% of total hepatic volume, baseline serum neuron-
specific enolase < 15 ng/mL, and NETs of small bowel 
origin.59,60
The goal of treatment with PRRT is therefore palliative in 
the form of symptomatic control in patients with functional 
NETs, tumour growth control, and improvement in quality 
of life.61 Sufficient down-staging of tumour may be achieved 
after PRRT allowing for tumour resection.
11. Disclaimer
This practice guidance document has been written by the 
College of Nuclear Physicians (CNP) of South Africa and 
endorsed by the South African Society of Nuclear Medicine 
(SASNM) and the Association of Nuclear Physicians (ANP) 
to assist Nuclear Physicians in providing appropriate care 
for patients and as an educational tool to promote cost-
effective use of PRRN in clinical practice and in research. 
These guidelines should be used as a guidance document for 
clinicians and not a set of rules to be rigidly applied to all 
patients. The judgement on the course of patient management 
should be made by the physician based on circumstances 
presented. In view of this, a course of action that differs from 
what is stated in this document is not necessarily below the 
standard of care. The CNP and the SASNM caution against 
the use of this guidance document as a legal standard of care 
or its use in litigation to challenge the clinical decisions of a 
practitioner. 
This document has been compiled based on recent 
published evidence in the literature on the use of PRRT in the 
management of differentiated NETs as well as the experience 
of leading practitioners in the field. Evidence advancing the 
practice of Nuclear Medicine emerges at a rapid rate. The date 
of publication of this document should be considered in the 
determination of its applicability at all times.
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